Can tofacitinib be used to treat lichen planus in a 25‑year‑old woman planning future pregnancy, and what are the recommended dosing, monitoring, and safety considerations?

Tofacitinib Should Generally Be Avoided in a 25-Year-Old Woman Planning Future Pregnancy

Tofacitinib is not recommended for lichen planus in women planning pregnancy due to teratogenic effects demonstrated in animal studies and limited human safety data, though it may be considered only if no effective alternatives exist to maintain maternal health. 1, 2, 3

Critical Pregnancy Considerations

Teratogenicity Risk

The FDA drug label clearly documents that tofacitinib was teratogenic in rabbits at 6.3 times the maximum human dose of 10 mg twice daily, causing thoracogastroschisis, omphalocele, ventricular septal defects, and cranial/skeletal malformations 3. While animal findings don't always translate directly to humans, this represents a significant safety signal.

Preconception Planning Requirements

If tofacitinib must be used:

• Discontinue at least 4 weeks before attempting conception (approximately 6 elimination half-lives) 1, 2
• Use effective contraception during treatment 1, 4
• The drug has a short plasma half-life, allowing relatively rapid clearance 1

Limited Human Data

While small case series show no consistent pattern of malformations in 74-128 reported pregnancies 2, 5, these numbers are insufficient to establish safety. The 2025 IBD pregnancy consensus states tofacitinib is "relatively contraindicated during pregnancy" 2.

If Treatment Is Absolutely Necessary

Dosing for Lichen Planus

Based on off-label use data:

• Start with 5 mg twice daily to minimize adverse effects 6, 7
• 10 mg twice daily shows higher efficacy but significantly increased infection and cytopenia risk 6
• Recent case series in hypertrophic lichen planus used mean dose of 11.6 mg daily (10-15 mg) for mean 8.8 weeks 7
• Response typically occurs within 1-2 months, with pruritus resolving in approximately 8-9 days 7, 8

Baseline Monitoring Requirements

Before initiating tofacitinib 6, 1, 9:

• Complete blood count with differential (do not start if lymphocytes <500/mm³, ANC <1000/mm³, or hemoglobin <9 g/dL)
• Liver function tests (avoid in severe hepatic impairment)
• Renal function tests
• Lipid profile
• Hepatitis B surface antigen, surface antibody, and core antibody
• Hepatitis C antibody
• HIV testing (if risk factors present)
• Tuberculosis screening (interferon-gamma release assay or PPD)
• Pregnancy test
• Consider Shingrix vaccination before starting (herpes zoster risk increases) 6, 9

Ongoing Monitoring

• CBC with differential every 3 months 6
• Liver and renal function every 3 months 6
• Lipid profile every 3-6 months 9
• Hold drug if lymphocytes <500/mm³, ANC <500/mm³, or hemoglobin drops ≥2 g/dL 6

Safety Concerns Beyond Pregnancy

Infection Risk

• Serious infections including tuberculosis, opportunistic infections, and herpes zoster 6
• Avoid during active serious infection 6
• Risk increases in patients >65 years 1

Malignancy

No clear signal in registries to date, but lymphomas occurred in animal studies at 3 times human dose 6

Thromboembolism

Black box warning for increased blood clots with higher doses 6. This is particularly relevant as the 10 mg twice daily dose sometimes used for psoriasis carries elevated VTE risk 1.

Alternative Approaches for This Patient

Given the pregnancy planning context, consider:

• Topical corticosteroids (clobetasol 0.05%) as first-line
• Intralesional triamcinolone for localized disease
• Hydroxychloroquine (safer pregnancy profile, though slower onset)
• Systemic corticosteroids for acute flares (compatible with pregnancy)
• Delay conception until disease is controlled with pregnancy-compatible agents

Common Pitfalls

1. Don't assume JAK inhibitors are interchangeable - tofacitinib is a pan-JAK inhibitor with different safety profile than selective JAK1 inhibitors 9
2. Don't combine with other potent immunosuppressants (azathioprine, cyclosporine) or biologics 6, 1
3. Don't give live vaccines during treatment 6
4. Don't ignore the 4-week washout period before conception 1, 2

Breastfeeding Considerations

If pregnancy occurs and breastfeeding is planned: Avoid breastfeeding or discontinue tofacitinib - the drug is present in human milk, and manufacturers recommend avoiding breastfeeding for 18 hours after the last dose of immediate-release formulation 3. The 2021 consensus states breastfeeding is contraindicated as a precautionary measure 1.